MariTide (Maridebart Cafraglutide): Amgen's Once-Monthly Obesity Drug

The obesity pharmacotherapy field has been defined by weekly injectables for the past three years. Amgen's MariTide breaks that cadence — it is dosed once a month and built on a mechanism no other approved obesity drug uses: GLP-1 receptor agonism paired with GIP receptor antagonism. In its phase 2 trial, the drug produced up to 20% mean body weight reduction over 52 weeks, with weight loss still trending downward at the trial's endpoint.

That headline number puts MariTide in the same efficacy tier as tirzepatide and retatrutide — but the mechanism, the dosing schedule, and the early data on weight maintenance after stopping treatment make it a genuinely distinct candidate. Here is what the evidence says, where the open questions sit, and how to read the next 18 months of trial readouts.

What MariTide Actually Is

MariTide (development code AMG 133, generic name maridebart cafraglutide) is not a small-molecule drug or a peptide in the traditional sense. It is a peptide–antibody conjugate: a fully human monoclonal antibody that blocks the GIP receptor, with two GLP-1 analogue peptides chemically tethered to it through amino-acid linkers.

That structure has two practical consequences:

• Half-life measured in weeks, not days. The antibody scaffold gives the molecule pharmacokinetics closer to a biologic than a peptide hormone. Once-monthly subcutaneous dosing is feasible — and so is the every-other-month dosing being explored in late-stage trials.
• A single molecule does two opposite things at two different receptors. The antibody arm sits on the GIP receptor and prevents endogenous GIP from binding. The GLP-1 peptide arm activates the GLP-1 receptor like semaglutide or liraglutide does.

Evidence: "AMG 133 is a bispecific molecule engineered by conjugating a fully human monoclonal anti-human GIPR antagonist antibody to two GLP-1 analogue agonist peptides using amino acid linkers." — Véniant MM, et al. Nat Metab. 2024. 10.1038/s42255-023-00966-w

The GIP Antagonism Paradox

Here is the part that confuses anyone coming from the tirzepatide playbook: tirzepatide activates the GIP receptor, while MariTide blocks it. Both approaches produce substantial weight loss. Why?

The honest answer from current research is that the field does not fully understand the paradox. Both genetic and pharmacologic data, however, support GIP antagonism as a viable strategy:

• Genetic data. Genome-wide association studies show that human GIP-receptor variants with reduced function correlate with lower BMI.
• Preclinical data. Both global and central nervous system knockout of GIP receptors protects mice on a high-fat diet from obesity and insulin resistance.
• Pharmacologic data. GIP antagonism amplifies GLP-1–induced weight loss in mice, monkeys, and now humans.

Evidence: "Beneficial effects are seen with both GIP receptor antagonism and GIP receptor agonism, although the mechanisms underlying this apparent paradox remain unknown." — Drucker DJ. Diabetes. 2025. PMC12278783

One leading hypothesis: chronic GIP-receptor activation may desensitize the receptor, so antagonism and prolonged agonism converge on similar downstream effects in adipose tissue and the central nervous system. Another: the two strategies act through different cell populations (peripheral adipocytes vs. hypothalamic neurons), and either one is sufficient to shift energy balance.

Phase 2 Trial: The 20% Number in Context

The pivotal phase 2 readout was published in The New England Journal of Medicine in 2025 after presentation at the American Diabetes Association's 85th Scientific Sessions. Two cohorts were studied: adults with obesity without type 2 diabetes, and adults with obesity with type 2 diabetes. Both received once-monthly subcutaneous MariTide for 52 weeks against placebo.

Headline Efficacy

Endpoint	Obesity (no T2D)	Obesity + T2D
Mean weight change at 52 wks	up to −20%	up to −17%
Placebo weight change	−2.6%	−1.4%
HbA1c reduction (T2D arm)	—	up to −2.2%

Two features of the curve matter as much as the headline number:

1. No plateau at 52 weeks. Weight loss was still trending downward at the final visit, suggesting the maximum effect had not been reached. This is uncommon — most GLP-1 monotherapy curves flatten by week 40–60.
2. Cardiometabolic improvements tracked the weight loss. Pre-specified secondary endpoints showed reductions in waist circumference, blood pressure, hs-CRP, and select lipid parameters.

Evidence: "Mean weight reductions of up to 20% in participants with obesity without type 2 diabetes and up to 17% in those with both obesity and type 2 diabetes." — Jastreboff AM, et al. NEJM. 2025. 10.1056/NEJMoa2504214

Tolerability — The Real Question

Phase 1 data had raised a tolerability flag: high rates of nausea and vomiting at the doses producing the strongest weight loss. The phase 2 trial directly addressed this with a slower titration schedule, and the redesign worked. Lower starting doses with gradual escalation substantially improved gastrointestinal tolerability without sacrificing efficacy at the target dose.

Wall Street analysts read the same data more pessimistically — discontinuation rates were higher than analysts modeled, and the stock dropped on the readout. Whether that translates into a meaningful real-world disadvantage versus weekly tirzepatide will depend on long-term phase 3 data.

How MariTide Compares to Other Obesity Drugs

MariTide enters a crowded but differentiated pipeline. The comparison table below is approximate and derived from independent phase 2/3 readouts — direct head-to-head trials do not yet exist for most pairings.

Drug	Mechanism	Dosing	Peak weight loss (phase 2/3)
Semaglutide (Wegovy)	GLP-1 agonist	Weekly	~15%
Tirzepatide (Zepbound)	GLP-1 + GIP agonist	Weekly	~22%
Retatrutide	GLP-1 + GIP + glucagon agonist	Weekly	~24%
CagriSema	GLP-1 + amylin agonist	Weekly	~22%
MariTide	GLP-1 agonist + GIP antagonist	Monthly	~20%

Two takeaways. First, MariTide's efficacy lands inside the "next-generation" cluster, not at the top of it. Second, it is the only candidate in late-stage development with a monthly dosing interval — a meaningful adherence and patient-experience advantage if the phase 3 data hold up.

What Phase 3 Will Need to Answer

Amgen has guided that phase 3 trials are launching across multiple indications. The clinical questions worth tracking:

Durability and Weight Maintenance

The biggest unmet need in obesity pharmacotherapy is what happens after patients stop. Most GLP-1 monotherapy data show roughly two-thirds of lost weight regained within a year of discontinuation. MariTide's antibody-based pharmacokinetics — with drug remaining biologically active for weeks after the last dose — may produce a more gradual washout and slower regain trajectory. Phase 3 protocols include extended off-treatment follow-up specifically to test this.

Cardiovascular Outcomes

Amgen has indicated phase 3 cardiovascular outcomes trials in atherosclerotic cardiovascular disease (ASCVD) and heart failure are planned, alongside an obstructive sleep apnea program. These are the trials that determine whether MariTide gets reimbursement parity with semaglutide and tirzepatide for non-weight indications.

Real-World Adherence

Monthly dosing changes the adherence math. A patient who misses a weekly injection is one week off-protocol; a patient who misses a monthly injection is a full month off-protocol. The design implication: forgiveness of missed doses depends on the molecule's tail. MariTide's long half-life is favorable here, but real-world data will matter.

Practical Implications for Clinicians and Patients

MariTide is not yet FDA-approved as of this writing. It cannot be prescribed off-label, compounded, or sourced through the channels that have served other GLP-1 drugs during shortages. Phase 3 readouts are expected through 2026–2028, with the earliest possible regulatory submission in that window.

For patients currently considering or already on a GLP-1 medication:

• Don't switch to wait. The pipeline is consistently 2–3 years behind initial expectations. Patients who delay current therapy hoping for the "next better drug" lose months of metabolic improvement.
• Monthly dosing is appealing but unproven at scale. Adherence advantages are intuitive but have not yet been demonstrated in head-to-head obesity trials. The injection-frequency premium may evaporate if monthly drugs cost more or carry harder titration.
• GIP antagonism may have a different side-effect profile long-term. Tirzepatide's GIP agonism has been linked to favorable lipid effects and possibly muscle preservation; antagonism could behave differently. This is a watch-this-space area, not a known concern.

Key Takeaways

• MariTide (maridebart cafraglutide, AMG 133) is a peptide–antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism in a single monthly subcutaneous injection.
• The phase 2 trial reported up to 20% mean weight loss at 52 weeks in adults with obesity, with the weight-loss curve still trending downward at the endpoint and HbA1c improvements up to 2.2% in patients with type 2 diabetes.
• Improved titration in phase 2 substantially reduced GI tolerability concerns versus phase 1, though discontinuation rates remain a question phase 3 will resolve.
• The drug is not yet approved; phase 3 cardiovascular, sleep apnea, and obesity outcomes trials are launching, with potential approval in the 2027–2028 window.

---

References

1. Jastreboff AM, Kaplan LM, Hartman ML, et al. Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2504214 — PMID: 40549887
2. Véniant MM, Lu SC, Atangan L, et al. A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024;6(2):290-303. DOI: 10.1038/s42255-023-00966-w — PMID: 38316982
3. Drucker DJ. GIP Receptor Antagonists in the Pharmacotherapy of Obesity: Physiologic, Genetic, and Clinical Rationale. Diabetes. 2025;74(8):1334-1342. PMID: 40521869 — PMC12278783
4. Campbell JE. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes. 2025;74(8):1326-1333. PMID: 40521890
5. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038

---

Last updated: 2026-05-04 Medical review: Dr. James Chen, MD, PhD, FACE